

25th November 2020

For personal use only PYC to present at Evercore ISI Conference

Highlights

- PYC Therapeutics has been invited to present at the 3rd Annual Evercore ISI Virtual HealthCONx Conference on December 2nd, 2020 at 9:45 AM US Eastern Time
- Evercore, a major US investment bank and advisor with a top rated biotechnology practice, holds the HealthCONx conference annually in Boston. Due to COVID-19 this years conference is being held virtually.
- PYC's management team will also host virtual investor meetings at the conference

Announcement

PYC Therapeutics, (ASX: PYC) ('The Company' or 'PYC') is pleased to announce The Company's participation at the 3rd Annual Evercore ISI Virtual HealthCONx Conference being held on December 1-3, 2020. The Company's Chief Scientific Officer, Professor Sue Fletcher will present at a fireside chat on Wednesday, December 2nd, 2020 at 9:45 AM US Eastern Standard Time.

In addition to the presentation, the management team will also host virtual investor meetings on December 2nd and 3rd at the conference. Investors participating in the conference who are interested in meeting with the PYC Therapeutics management should contact their Evercore representative.

ENDS

For further information, please contact:

INVESTORS
Kaggen Ausma
CBO
info@pyctx.com

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a drug development company based in the United States and Australia, progressing life-changing science towards areas of important unmet patient need.

The Company combines world-leading RNA therapeutics design with a revolutionary delivery technology based on Cell Penetrating Peptides (CPPs) to overcome the major challenges of current gene-therapies. PYC's CPPs solve the 'delivery challenge', providing safe and effective access for a wide range of potent and precise drug cargoes to the highest value drug targets that exist inside cells. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies with an initial focus on inherited eye diseases for which PYC has 3 defined pre-clinical programs.

About Vision Pharma

Vision Pharma Pty Ltd (Vision) is a joint venture between PYC Therapeutics (PYC) and the Lions Eye Institute (LEI) dedicated to the development of new treatments for a range of debilitating eye diseases. Vision is advancing a lead program for the treatment of a form of Retinitis Pigmentosa as well as a range of other precision medicines for different eye diseases. Vision combines the clinical expertise of LEI with the drug development capabilities of PYC and is owned according to a 90% (PYC) and 10% (LEI) shareholding distribution.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Tel: +61 8 6151 0994

pyctx.com

PYC Therapeutics Limited

ACN 098 391 961